Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple-Reference-Cited by-同舟云学术

Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple

Published:2020-04-20 Issue:3 Volume:38 Page:363-371
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Schütz Natalia P.¹^ORCID,Ochoa Paola²,Duarte Patricio³,Remaggi Guillermina⁴,Yantorno Sebastián⁵,Corzo Ariel⁶,Zabaljauregui Soledad⁷,Shanley Claudia⁸,Lopresti Sergio⁹,Orlando Sergio¹⁰,Verri Verónica¹¹,Quiroga Luis¹²,García Carlos A.¹³,Fernández Vanesa¹⁴,Fantl Dorotea¹

Affiliation:

1. Hospital Italiano de Buenos Aires – Servicio de Clínica Médica (Sección Hematología) Buenos Aires Argentina

2. Instituto Alexander Fleming – Departamento de Hematología Buenos Aires Argentina

3. CEMIC – Sección Hematología Buenos Aires Argentina

4. FUNDALEU – Departamento de Trasplante de Médula ósea Buenos Aires Argentina

5. Hospital Italiano de La Plata – Servicio de Hematología (Unidad de Trasplante de Médula ósea) Buenos Aires Argentina

6. Hospital de Clínicas “José de San Martín” – Departamento de Clínica Médica (División Hematología) Buenos Aires Argentina

7. Academia Nacional de Medicina – Departamento de Hemato‐Oncología (División Oncohematología) Buenos Aires Argentina

8. Hospital Británico – Departamento de Hematología (Unidad de Trasplante de Médula ósea) Buenos Aires Argentina

9. Hospital Posadas – Departamento de Medicina Interna Morón Argentina

10. Hospital Rodolfo Rossi – Departamento de Hematología y Trasplante de Médula ósea La Plata Argentina

11. Instituto de Investigaciones Médicas “Alfredo Lanari” UBA – Departamento de Hematología Buenos Aires Argentina

12. Complejo Médico de la Policía Federal Argentina Churruca Visca – Departamento de Clínica Médica (Sección Hematología) Buenos Aires Argentina

13. Clínica 25 de Mayo Mar del Plata Argentina

14. Sanatorio Dr. Julio Méndez – Departamento de Clínica Médica (Sección Hematología) Buenos Aires Argentina

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2729

Reference19 articles.

1. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

2. Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes

3. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making

4. United Nations Statistic Division.https://unstats.un.org/unsd/environment/totalarea.htm. Accessed November 11 2019.

5. United Nations Population Division.https://population.un.org/wpp/Publications/Files/WPP2017_Volume-II-Demographic-Profiles.pdf. Accessed November 12 2019.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The 5T's of health disparities in multiple myeloma in Latin America;Current Opinion in Oncology;2024-09-09

2. Multiple myeloma in Latin America: A systematic review;eJHaem;2024-06-10

3. Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant‐eligible multiple myeloma patients failing front‐line bortezomib‐based induction therapy—ALLG MM21;British Journal of Haematology;2024-06-08

4. Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients;Annals of Saudi Medicine;2024-03

5. Real-world effectiveness and safety of multiple myeloma treatments based on thalidomide and bortezomib: A retrospective cohort study from 2009 to 2020 in a Brazilian metropolis;Cancer Epidemiology;2023-08